World‑first experimental cancer treatment paves way for clinical trial
Neoadjuvant trimeric immune checkpoint blockade is feasible and effective in newly diagnosed glioblastoma
A peer‑reviewed study reports the first use of neoadjuvant triple immunotherapy (checkpoint blockade) in a patient with newly diagnosed glioblastoma, demonstrating prolonged disease control and suggesting feasibility for a larger clinical trial.
This novel approach could transform standard care for glioblastoma, potentially improving survival in a disease with poor prognosis.
Evidence level: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Related signals
- Glioma
- Glioblastoma Clinical Trials for New Treatments
- Clinical trial links oncolytic immunoactivation to survival in glioblastoma
- Treating the invisible target: treatment planning targeting the microscopic tumor spread in gliomas
- EGFR inhibition down-regulates MGMT and enhances responsiveness to temozolomide in glioblastoma